Familial Amyloid Cardiomyopathy Treatment Market Technology & Market Analysis Report
Familial Amyloid Cardiomyopathy Treatment Market – Insights
Familial amyloid cardiomyopathy (FAC), also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy, is the aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart. The condition is more prevalent in geriatric population. The protein transthyretin amyloid fibrils infiltrates the myocardium, thereby leading to diastolic dysfunction from restrictive cardiomyopathy. This in turn increases the risk of heart failure. V1221, P24S, V20I, A45T, Gly47Val, I68L, L111M, Glu51Gly, and Gln92Lys are...
View full press release